WO2014007423A1 - Culture composition for inducing dendritic cells from peripheral blood, culture kit comprising the same, and method for inducing dendritic cells from peripheral blood using the same - Google Patents
Culture composition for inducing dendritic cells from peripheral blood, culture kit comprising the same, and method for inducing dendritic cells from peripheral blood using the same Download PDFInfo
- Publication number
- WO2014007423A1 WO2014007423A1 PCT/KR2012/006320 KR2012006320W WO2014007423A1 WO 2014007423 A1 WO2014007423 A1 WO 2014007423A1 KR 2012006320 W KR2012006320 W KR 2012006320W WO 2014007423 A1 WO2014007423 A1 WO 2014007423A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendritic cells
- peripheral blood
- culture composition
- culture
- blood
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 41
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 41
- 230000001939 inductive effect Effects 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 23
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 26
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims abstract description 18
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000001768 cations Chemical class 0.000 claims abstract description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 14
- 102000004877 Insulin Human genes 0.000 claims abstract description 13
- 108090001061 Insulin Proteins 0.000 claims abstract description 13
- 229940125396 insulin Drugs 0.000 claims abstract description 13
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 12
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 12
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 12
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 12
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 12
- 239000011720 vitamin B Substances 0.000 claims abstract description 12
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 9
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims abstract description 8
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims abstract description 8
- 229940047120 colony stimulating factors Drugs 0.000 claims abstract description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 16
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- 238000011534 incubation Methods 0.000 claims description 15
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 14
- 102100025136 Macrosialin Human genes 0.000 claims description 14
- -1 CDllc Proteins 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002771 cell marker Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 claims description 3
- 235000008160 pyridoxine Nutrition 0.000 claims description 3
- 239000011677 pyridoxine Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 24
- 238000003364 immunohistochemistry Methods 0.000 description 14
- 238000010186 staining Methods 0.000 description 13
- 210000000601 blood cell Anatomy 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 8
- 230000024245 cell differentiation Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000032823 cell division Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010052234 Citrate toxicity Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
Abstract
The present invention relates to a culture composition for inducing dendritic cells from peripheral blood, a culture kit comprising the same, and a method for inducing dendritic cells from peripheral blood using the same, and more particularly, to a culture composition for inducing dendritic cells from peripheral blood, comprising adenosine triphosphate (ATP), a divalent cation, a chloride, vitamin B, insulin, G-CSF (Granulocyte colony-stimulating factors), erythropoietin, and a solvent, a culture kit comprising the same, and a method for inducing dendritic cells from peripheral blood using the same.
Description
[DESCRIPTION]
[invention Title]
CULTURE COMPOSITION FOR INDUCING DENDRITIC CELLS FROM PERIPHERAL BLOOD, CULTURE KIT COMPRISING THE SAME, AND METHOD FOR INDUCING DENDRITIC CELLS FROM PERIPHERAL BLOOD USING THE SAME
[Technical Field]
[0001] This application claims the priority of Korean Patent Application No. 10-2012-0073804 filed on July 06, 2012, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference.
[0002] The present invention relates to a culture composition for inducing dendritic cells from peripheral blood, a culture kit comprising the same, and a method for inducing dendritic cells from peripheral blood using the same, and more particularly, to a culture composition allowing for the induction of CD14, CDllc, and CD68 positive dendritic cells from leukocytes obtained from peripheral blood, a culture kit comprising the same, and a method for inducing CD14, CDllc, and CD68 positive dendritic cells using the same.
[Background Art]
[0003] Dendritic cells may be seen as representative antigen-presenting cells, which mainly perform an antigen-presenting function to T cells, and are present in intercellular spaces in various tissues, including lymphatic system tissue, in arborescent form.
[0004] While dendritic cells are somewhat similar to reticular
cells or dendritic macrophages, dendritic cells do not form connective tissues, and thus, cannot perform phagocytosis. Dendritic cells are derived from hematopoietic stem cells in bone marrow. They express class I and class II histocompatibility antigens on the cell surface and play an important role in activating T cells in an immune response.
[0005] Dendritic cells are distributed in small quantities in tissues in contact with the external environment, such as in the skin, inside the nostrils, in the lungs, in the stomach, in the intestines, and in other parts of. the body, and are also present in an immature state in the blood in an amount of 1% or less of the overall amount of immune cells.
[0006] Dendritic cells derived from monocytes have been acknowledged for the possibility of being stem cells which could repair damaged tissues and cells (Jalees R, Jingling L, Christie M, Keith L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secret angiogenic growth factors. Circulation 107, 1164-1169 (2003); Liang-Ji Z, Thomas F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc .Natl .Acad. Sci . USA 93, 2588-2593 (1996)), and it is known that dendritic cells play an important role as antigen presenting cells, which deliver antigens to lymphocytes in the cell-mediated immune system. Thus, dendritic cells are important for developing anticancer vaccines and cell therapy products for treating autoimmune diseases (Yeongcheol Seong, Yeontak Jin, Anticancer vaccines; Daehui Lee, Immunotherapy using dendritic cells, anticancer vaccines using dendritic cells) .
[0007] Meanwhile, it is known that when dendritic cells are derived
from peripheral circulating blood, they are CD14 positive, and as blood corpuscles differentiate into dendritic cells, CDllc and CD68 cell markers are positive (Jacques Bancherenn: Immunobiology of dendrite cells, Annu Rev Immunol 18, 767-81(2000)). More particularly, CD14 positive, CDllc positive, and GDI negative cell lines are precursor cells which can be differentiated into dendritic cells, and when these precursor cells are differentiated into dendritic cells, CD68 is expressed.
[0008] The origin of dendritic cells is circulating monocytes. However, the amount of monocytes in peripheral blood is low (1-5%) and it is difficult to direct monocytes to differentiate into dendritic cells. Alternately, mesenchymal stem cells such as bone marrow mesenchymal stem cells may be directed to differentiate into dendritic cells. However, dendritic cells derived from monocytes only have a therapeutic effect on autoimmune diseases and an anticancer effect, while the mesenchymal stem cells only function as multipotential stem cells.
[0009] Meanwhile, hematopoiesis in the human body is a one-way process of differentiation from multipotential hematopoietic stem cells to functional mature differentiated cells, such as granulocytes, monocytes, lymphocytes and the like, as shown in FIG. 1.
[Disclosure]
[Technical Problem]
[0010] Thus, if it is possible to direct differentiation-completed peripheral blood, in particular, mature leukocytes, to differentiate dendritic cells, it is expected that after directed
incubation of dendritic cells in vitro has been successfully undertaken, research and clinical applications undertaken with dendritic cells will be practicable in various fields associated with the treatment of autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, anticancer vaccines, cell therapy products, and other diseases.
[Technical Solution]
[0011] An aspect of the present invention provides a culture composition for inducing dendritic cells from peripheral blood.
[0012] Another aspect of the present invention provides a culture kit for inducing dendritic cells from peripheral blood.
[0013] Another aspect of the present invention provides a method for inducing dendritic cells using the culture composition and the culture kit.
[0014] According to an aspect of the present invention, there is provided a culture composition for inducing dendritic cells from peripheral blood, comprising adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
[0015] The induced dendritic cells may be CD14, CDllc, and CD68 cell marker positive.
[0016] The divalent cation may be one or more selected from the group consisting of Zn2+, Cu2+, Mg2+, and Cr2+.
[0017] The chloride may be one or more selected from the group consisting of potassium chloride and bromine chloride.
[0018] The vitamin B may be vitamin B6 (pyridoxine) .
[0019] The solvent may be distilled water.
[0020] The culture composition may comprise 25-35 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 190-210 mg of the chloride, 45-55 mg of vitamin B, 0.5-1.5 I. U. of insulin, 15-25 pg of Granulocyte colony-stimulating factors (G-CSF) , 450-550 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc.
[0021] According to another aspect of the present invention, there is provided a culture kit for inducing dendritic cells from peripheral blood, comprising an airtight sterile container, which contains the above culture composition, and in which internal pressure is controlled to be equal to external pressure thereof.
[0022] According to another aspect of the present invention, there is provided a method for inducing dendritic cells from peripheral blood, comprising: mixing blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma; pouring the obtained buffy coat and plasma into an airtight sterile container, which contains the culture composition, and in which internal pressure is controlled to be equal to external pressure thereof; and inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
[0023] The incubation may be carried out for from about 50 hours to about 200 hours.
[0024] The incubation may be carried out at a temperature from about 34 to 36 °C.
[0025] The induced dendritic cells may be CD14, CDllc, and CD68 cell marker positive.
[Advantageous Effects]
[0026] With the culture composition, the culture kit of the present invention for inducing dendritic cells from leukocytes obtained from peripheral blood, and the method for inducing dendritic cells using the same of the present invention, a large amount of dendritic cells can be easily obtained from peripheral blood obtained from adults. Thus, the obtained dendritic cells can be used in various fields associated with the treatment of autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, and in cell therapy products which can induce the reduction and destruction of tumors, and the like.
[Description of Drawings]
[0027] The above and other aspects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a diagram illustrating the differentiation process from hematopoietic stem cells to mature blood cells;
FIG. 2(a) illustrates the culture composition of the present invention, FIG.2 (b) illustrates the result directly after pouring the buffy coat and plasma into the culture composition of the present invention, and FIG. 2(c) illustrates the result after incubating the culture kit of the present invention for 4 weeks; and
FIGS. 3 to 5 illustrate results obtained by incubating peripheral blood samples for 28 days under the same conditions using the culture kit of the present invention, into which three groups of peripheral blood samples were poured, upon which
immunohistochemistry staining was carried out, and then peripheral blood samples were observed under a microscope (X400) . In respective FIGS. 3 to 5, (a) illustrates the result of immunohistochemistry staining for CD14, (b) illustrates the result of immunohistochemistry staining for CDllc, and (c) illustrates the result of immunohistochemistry staining for CD68.
[Best Mode]
[0028] Exemplary embodiments of the present invention will now be described in detail with reference to the accompanying drawings.
[0029] According to the present invention, there is provided a culture composition for inducing dendritic cells from peripheral blood. According to the culture composition of the present invention, dendritic cells can be obtained from differentiation-completed blood corpuscles in peripheral blood, in particular, leukocytes.
[0030] According to the present invention, dendritic cells which are CD14, CDllc, and CD68 positive can be obtained from leukocytes obtained from peripheral blood. It is known that when dendritic cells are derived from peripheral circulating blood, they are CD14 positive, and as blood corpuscles differentiate into dendritic cells, CDllc and CD68 cell markers are positive.
[0031] More particularly, according to the present invention, dendritic cells can be induced from a buffy coat isolated from peripheral blood, and especially, dendritic cells can be induced from leukocytes contained in the buffy coat.
[0032] The culture composition of the present invention comprises adenosine triphosphate (ATP) , a divalent cation, a chloride,
vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
[0033] In the present invention, water may be used for the solvent, and preferably, distilled water may be used for the solvent.
[0034] Adenosine triphosphate is also known as ATP, and functions as an energy source for facilitating and maintaining the differentiation into dendritic cells in the culture composition.
[0035] The ATP may be comprised in an amount of 25 to 35 mg, and preferably, 28 to 32 mg, based on the final volume of the culture composition of the present invention being 8 cc. Where the ATP is comprised in an amount of less than 25 mg or more than 35 mg, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than dendritic cells .
[0036] The divalent cation is a component designed to stabilize cell membrane and balance electrolytes in the culture composition of the present invention, and may be one or more selected from the group consisting of Zn2+, Cu+, Mg2+, and Cr2+, and preferably, Zn2+. The divalent cation may be included as an appropriate salt known to the art, including sulfates, citrates, and the like such as copper sulfate, magnesium sulfate, zinc sulfate, and the like.
[0037] In the present invention, the term 'one or more' means that each component may be used alone, or two or more components may be used in combination.
[0038] The divalent cation may be comprised in an amount of 5 to 7 mg, and preferably, 5.2 to 6.6 mg, based on the final volume of the culture composition of the present invention being 8 cc.
[0039] Where the divalent cation is comprised in an amount of less than 5 mg, there may be a problem in which the directed
differentiation into dendritic cells may be insufficient. Where the divalent cation is comprised in an amount of more than 7 mg, there is a concern that cells may die due to high osmotic pressure of a culture medium.
[0040] The chloride comprised in the present invention plays a role in stabilizing cations and maintaining a suitable concentration of a culture medium in the culture composition. The chloride may be one or more selected from the group consisting of potassium chloride and bromine chloride, and preferably, potassium chloride .
[0041] The chloride may be comprised in an amount of 100 to 200 mg, and preferably, 130 to 170 mg, based on the final volume of the culture composition of the present invention being 8 cc.
[0042] Where the chloride is comprised in an amount of less than 100 mg, there may be a problem in which the osmotic pressure is lowered too far and where the chloride is comprised in an amount of more than 200 mg, there may be a problem in which the osmotic pressure is raised too high. When the osmotic pressure is lowered or raised by too much as above, it may have adverse affects on a cell culture, and the induction of dendritic cells may not be achieved smoothly.
[0043] The vitamin B may be vitamin B6 (pyridoxine) , and the vitamin B acts as a catalyst for cell division in the culture composition.
[0044] The vitamin B may be comprised in an amount of 45 to 55 mg, and preferably, 48 to 52 mg, based on the final volume of the culture composition of the present invention being 8 cc.
[0045] Where vitamin B6 is comprised in an amount of less than 45 mg, there is a problem with the efficiency of cell division and differentiation, and where vitamin B6 is comprised in an amount
of more than 55 mg, there is a concern for an occurrence of cytotoxicity.
[0046] Insulin acts as a messenger for cell differentiation in the culture composition, and R (Regular) insulin may be used for the insulin.
[0047] The insulin may be comprised in an amount of 0.5 to 1.5 I .U. , and preferably, 0.8 to 1.2 I.U., based on the final volume of the culture composition of the present invention being 8 cc .
[0048] Where the insulin is comprised in an amount of less than 0.5 I.U., there may be a problem in which the efficiency of cell division and differentiation may be deteriorated, and where the insulin is comprised in an amount of more than 1.5 I.U. , there may be a problem in which the blood corpuscles may differentiate into a type of cell other than dendritic cells.
[0049] Granulocyte colony-stimulating factors (G-CSF) , also known as filgrastim, act as a messenger for inducing differentiation in the cell differentiation process, and recombinant G-CSF may be used for the G-GSF.
[0050] The G-CSF may be comprised in an amount of 15 to 25 iq, and preferably, 18 to 22 g, based on the final volume of the culture composition of the present invention being 8 cc.
[0051] Where the G-CSF is comprised in an amount of less than 15 μς or more than 25 ig, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than dendritic cells.
[0052] The erythropoietin also plays a role in inducing differentiation in the cell differentiation process, and recombinant erythropoietin may be used for the erythropoietin.
[0053 ] The erythropoietin may be comprised in an amount of 450 to 550 I. U. , and preferably, 180 to 520 I. U. , based on the final volume of the culture composition of the present invention being 8 cc.
[0054] Where the erythropoietin is comprised in an amount of less than 450 I.U. or more than 550 I.U., there may be a problem that the blood corpuscles may differentiate into a type of cells other than dendritic cells.
[0055] Most preferably, the culture composition of the present invention may comprise 25-35 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 190-210 mg of the chloride, 45-55 mg of vitamin B, 0.5-1.5 I.U. of insulin, 15-25 g of Granulocyte colony-stimulating factors (G-CSF) , 450-550 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc.
[0056] Meanwhile, according to the present invention, there is provided a culture kit for inducing dendritic cells from peripheral blood. The culture kit of the present invention comprises an airtight container containing the above described culture composition of the present invention.
[0057 ] Furthermore, the culture kit may comprise an airtight sterile container, in which internal pressure is controlled to be equal to external pressure thereof.
[0058] A container usable for the culture kit of the present invention may be a sterilized airtight container. Materials for the container are not particularly limited, and any container which is suitable for culture growth may be usable, and glass may be used for the material of the container. However, any other appropriate container known to the art, which can contain the culture
composition safely and culture cells, may be used. Most preferably, vials may be used for the container.
[0059] The container may contain the culture composition of the present invention in an amount from about 7/50 to about 9/50 of the overall volume.
[0060] Furthermore, according to the present invention, there is provided a method for inducing dendritic cells from peripheral blood.
[0061] The method of the present invention uses the above culture composition and the culture kit of the present invention, and more particularly, comprises mixing peripheral blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma; pouring the obtained buffy coat and plasma into the airtight sterile container, which contains the culture composition of the present invention, and in which internal pressure is controlled to be equal to external pressure thereof; and inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
[0062] The culture composition and the culture kit comprising the same, which are used for the method for inducing dendritic cells from peripheral blood of the present invention, are the same as described above .
[0063] More particularly, for the method for inducing dendritic cells of the present invention, first, in order to prevent the coagulation of blood obtained from humans, the blood is mixed with anticoagulant, followed by centrifuging to obtain a buffy coat and plasma.
[0064] Here, the blood may be peripheral blood, which is obtained
from the periphery of the human body. The peripheral blood may be more preferably obtained from a vein. For example, the peripheral blood may be obtained from veins in arms , legs or other extremities .
[0065] Here, the usable anticoagulant may be, but not limited to, one or more selected from the group of sodium citrate and heparin.
[0066] The anticoagulant may be mixed in a ratio of 6 to 7 parts by weight, and preferably, about 6.6 parts by weight, based on 100 parts by weight of peripheral blood. Where the anticoagulant is mixed in a ratio of less than 6 parts by weight based on 100 parts by weight of peripheral blood, the anticoagulant effect may be insufficient, and where the anticoagulant is mixed in a ratio of more than 7 parts by weight, there may be a problem in which citrate toxicity may occur.
[0067 ] The centrifugation for separating blood components may be carried out in a range of 1500 to 1700 rpm for 20 to 25 minutes, and more preferably, in a range of 1600 to 1700 rpm for 22 to 24 minutes .
[0068] Where the centrifugation is carried out at less than 1500 rpm or for less than 20 minutes, there may be a problem in which the centrifugation may be carried out insufficiently. Where the centrifugation is carried out at more than 1700 rpm or for more than 25 minutes, there is a concern that cells may be damaged.
[0069] Once the centrifugation is completed, blood is divided into three layers. The bottom layer occupies about 45%, and is comprised of erythrocytes (red blood cells) . The middle layer occupies about 1%, and is comprised of leukocytes (white blood cells) and platelets , and known as a ¾buffy coat' . The topmost layer occupies about 54%, and is comprised of plasma.
[0070] Into the airtight sterile container, which contains the culture composition of the present invention, and in which internal pressure is controlled to be equal to external pressure thereof, the buffy coat layer and the plasma layer isolated in the centrifugation detailed above are poured. External pressure refers to atmospheric pressure, and the method for controlling the pressure may be carried out by, for example, penetrating a syringe needle into a rubber stopper (rubber packing) , followed by removing the syringe needle if the pressures are in equilibrium but is not limited thereto.
[0071] Subsequently, the buffy coat layer and the plasma layer- poured container are incubated in a low temperature incubator . Here , the low temperature incubation may be carried out for 50 to 200 hours, and preferably, for 70 to 160 hours. Where the incubation is carried out for less than 50 hours, there may be a problem in which the incubation may be insufficient. Where the incubation is carried out for more than 200 hours, there may be a problem in which cell concentration may increase excessively in the culture composition and thus, apoptosis or cell suicide may occur.
[0072] The incubation may be carried out at a temperature from 34 to 36 °C, and more preferably, at about 35 °C. Where the incubation is carried out at less than 34 °C, there may be a problem in which the efficiency of cell differentiation may be decreased. Where the incubation is carried out at more than 36 °C, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than dendritic cells.
[0073] Hereinafter, the present invention will be described in more detail with reference to specific embodiments. However, the
following embodiments are described for illustrative purposes only, and do not limit the scope of the present invention.
[Mode for Invention]
[0074] Embodiments
[0075] <Embodiments>
[0076] 1. Preparation of culture kit comprising culture medium
[0077] To prevent coagulation, 30 cc of blood extracted from a vein was mixed with 2 cc of a citrate buffer (2.45 g of dextrose, 2.2 g of sodium citrate, and 730 mg citrate are contained in 100 cc of the citrate buffer) (Fenwal) to prepare a mixed solution.
[0078] The mixed solution was centrifuged at 1670 rpm for 24 minutes, and from the separated blood, a buffy coat and plasma were collected with a pipette, and poured into a culture kit, an airtight 50 cc glass bottle.
[0079] For the buffy coat and plasma obtained by the centrifugation of 30 cc of blood, the culture composition comprising the following components described in Table 1 was contained in the culture kit, and distilled water was added as a solvent thereto to make up the final volume of the whole composition to 8 cc.
[0080]
[Table l]
[0081] A 27 gauge syringe was inserted into a rubber stopper (rubber packing) on the airtight glass bottle, and removed if the pressures were in equilibrium to allow internal and external pressures to be equal .
[0082] FIG. 2(a) illustrates the culture composition of the present invention, FIG. 2 (b) illustrates the result directly after pouring the buffy coat and plasma into the culture composition of the present invention, and FIG. 2(c) illustrates the result after incubating the culture kit of the present invention for 4 weeks .
[0083] 2. Induction process of dendritic cells from peripheral blood
[0084] Blood samples were collected from three volunteers. Three groups of the culture kits as prepared in "1." were formed and incubated for 28 days under the same conditions. The incubation temperature was 35 °C.
[0085] 3. Confirmation of results for dendritic cell induction
[0086] (1) Immunohistochemistry staining
[0087] After incubation, each sample contained in each culture kit was aspirated by a syringe and placed into a 10 mL test tube. Then, each tube was centrifuged at 3000 rpm for 10 minutes at room temperature, and pellets that sank to the bottom and were isolated
were collected and embedded in paraffin to be fixed in 10% formalin solution. Cell blocks embedded in paraffin were formed, and then, to perform a hematoxylin-eosin staining, sections for each sample were prepared, and immunohistochemistry staining was carried out. Bond-MAX (Leica) equipment was used in immunohistochemistry staining.
[0088] As described above, after the immunohistochemistry staining, observation was made under a microscope (X400) . The results for a first, second, and third group are shown in FIG. 3, FIG. 4, and FIG. 5, respectively.
[0089] A list of antibodies in the immunohistochemistry experiment for confirming the cell differentiation into dendritic cells is CD14, CDllc, and CD68. Markers for immunohistochemistry staining used in this experiment were as per the following Table 2.
[0090]
[Table 2]
[0091] Meanwhile, the information on the staining reagent for immunohistochemistry used in this experiment is as follows:
Leica Microsystems
Bond TM Polymer Refine Detection
Catalog No: DS9800
[0092] From FIGS. 3 to 5, (a) illustrates the result of
immunohistochemistry staining for CD14, (b) illustrates the result of immunohistochemistry staining for CDllc, and (c) illustrates the result of immunohistochemistry staining for CD68. [0093] (2) Conclusion
[0094] Referring to FIGS.3 to 5, as shown in the above experiment, after 4 weeks of incubation, all of CD14, CDllc, and CD68-expressed cells were identified. This indicates that dendritic cells are induced by the present invention. Experiment for three groups showed the same results.
[0095] Referring to FIGS. 3 to 5, as the result of the experiment, cell components having two groups of nuclei comprising small lymphocyte-like nuclei with a large amount of platelets and a small amount of cytoplasms, and a small amount of lymphocyte or monocyte-like nuclei with a large amount of cytoplasms were identified. Both groups of cells exhibited strong immunoreactivity for all of CD14 , CDllc, and CD68.
[0096] That is, this result confirms that dendritic cells were induced from mature peripheral leukocytes with the use of the culture composition, the culture kit, and the method of the present invention.
[0097 ] While the present invention has been shown and described in connection with the exemplary embodiments, it will be apparent to those skilled in the art that modifications and variations can be made without departing from the spirit and scope of the invention as defined by the appended claims.
Claims
[CLAIMS]
[Claim l]
A culture composition for inducing dendritic cells from peripheral blood, comprising adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent .
[Claim 2]
The culture composition of claim 1, wherein the induced dendritic cells are CD14, CDllc, and CD68 cell marker positive.
[Claim 3]
The culture composition of claim 1, wherein the divalent cation is one or more selected from the group consisting of Zn2+, Cu2+, Mg2+, and Cr2+.
[Claim 4]
The culture composition of claim 1, wherein the chloride is one or more selected from the group consisting of potassium chloride and bromine chloride.
[Claim 5]
The culture composition of claim 1, wherein the vitamin B is vitamin B6 (pyridoxine) .
[Claim 6]
The culture composition of claim 1, wherein the solvent is distilled water.
[Claim 7]
The culture composition of claim 1, comprising 25-35 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 190-210 mg of the chloride, 45-55 mg of vitamin B, 0.5-1.5 I.U. of insulin, 15-25 μq of Granulocyte colony-stimulating factors (G-CSF) , 450-550 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc . [Claim 8]
A culture kit for inducing dendritic cells from peripheral blood, comprising an airtight sterile container, which contains the culture composition of any of claims 1 to 7 , and in which internal pressure is controlled to be equal to external pressure thereof.
[Claim 9]
A method for inducing dendritic cells from peripheral blood, comprising:
mixing blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma;
pouring the obtained buffy coat and plasma into an airtight sterile container, which contains the culture composition of any of claims 1 to 7, and in which internal pressure is controlled to be equal to external pressure thereof; and
inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
[Claim 10]
The method of claim 9, wherein the incubation is carried out for from about 50 hours to about 200 hours.
[Claim ll]
The method of claim 9, wherein the incubation is carried out at from about 34 to about 36 °C.
[Claim 12]
The method of claim 9, wherein the induced dendritic cells are CD14 , CDllc, and CD68 cell marker positive.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120073804A KR101290061B1 (en) | 2012-07-06 | 2012-07-06 | Culture composition, and culture kit for inducing from peripheral blood to dendritic cells, and method for inducing dendritic cells from peripheral blood using the same |
| KR10-2012-0073804 | 2012-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014007423A1 true WO2014007423A1 (en) | 2014-01-09 |
Family
ID=48998103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2012/006320 WO2014007423A1 (en) | 2012-07-06 | 2012-08-08 | Culture composition for inducing dendritic cells from peripheral blood, culture kit comprising the same, and method for inducing dendritic cells from peripheral blood using the same |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101290061B1 (en) |
| WO (1) | WO2014007423A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230106434A (en) | 2022-01-06 | 2023-07-13 | 한국과학기술원 | Culture method for the dendritic cell differentiation and growth induction by modulating surface energy of culture substrate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070114378A (en) * | 2005-02-28 | 2007-12-03 | 리제네텍 인코포레이티드 | Method of providing readily available cellular material derived from peripheral blood and a composition thereof |
-
2012
- 2012-07-06 KR KR1020120073804A patent/KR101290061B1/en active IP Right Grant
- 2012-08-08 WO PCT/KR2012/006320 patent/WO2014007423A1/en active Application Filing
Non-Patent Citations (4)
Also Published As
| Publication number | Publication date |
|---|---|
| KR101290061B1 (en) | 2013-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2735139C2 (en) | Derived from human thrombocyte lysate, extracellular vesicles for use in medicine | |
| HU205380B (en) | Simplified process for producing killer cells activated with human lymphokine | |
| US11435350B2 (en) | Methods of analysis of blood from deceased donors | |
| US20220305057A1 (en) | Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells | |
| CN115364227A (en) | Methods of treating peripheral vascular disease using protein solutions | |
| CN106754723B (en) | Immune cell with anti-tumor function and application thereof | |
| CN113164517A (en) | Cell compositions derived from dead donors for promoting graft tolerance and their manufacture and use | |
| ES2705704T3 (en) | Method of obtaining a composition rich in cytokines and composition obtained by this method | |
| WO2014007423A1 (en) | Culture composition for inducing dendritic cells from peripheral blood, culture kit comprising the same, and method for inducing dendritic cells from peripheral blood using the same | |
| WO2014007421A1 (en) | Culture composition for inducing activated t lymphocytes from peripheral blood, culture kit comprising the same, and method for inducing activated t lymphocytes from peripheral blood using the same | |
| Peng et al. | Mesenchymal stromal cells and their small extracellular vesicles in allergic diseases: From immunomodulation to therapy | |
| US20200086004A1 (en) | Methods of making cellular compositions derived from deceased donors to promote graft tolerance | |
| WO2014007422A1 (en) | Composition for preserving platelets, kit for preserving platelets comprising the same, and method for preserving platelets using the same | |
| Xiong et al. | Emerging role of extracellular vesicles in veterinary practice: novel opportunities and potential challenges | |
| US20220264871A1 (en) | Cell cryopreservation solution and method for cryopreserving cells | |
| CN115518075B (en) | Cell composition and medical use thereof | |
| US20200038451A1 (en) | Stem cells as an individualized maternal therapy for prevention of prematurity | |
| CN116763817A (en) | Use of blood-derived samples for preparing vesicles | |
| CN115531521A (en) | Cell therapeutic agent, and preparation method and use thereof | |
| CN111803520A (en) | Acupoint injection for improving immune function | |
| NZ748679B2 (en) | Human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles for use in medicine | |
| TW201723172A (en) | Shrimp lymphocytes, method of purifying the same and method for in vitro evaluating innate immune response using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12880324 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12880324 Country of ref document: EP Kind code of ref document: A1 |